Andrea Anampa-Guzmán

Andrea Anampa-Guzmán

Auto-generated profile, based on publicly available information

Andrea Anampa-Guzmán

Faculty of Medicine, Universidad Nacional Mayor de San Marcos, Lima, Peru

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2022 in JCO Oncology Practice
Verified
Journal Article
Closed access
AAAndrea Anampa-Guzmán
Andrea Anampa-Guzmán
JFJanet Freeman-Daily
Janet Freeman-Daily
MFMichael Fisch
Michael Fisch
ELEmil Lou
Emil Lou
NPNathan A. Pennell
Nathan A. Pennell
FOfor the Collaboration for Outcomes using Social Media in Oncology
for the Collaboration for Outcomes using Social Media in Oncology
PURPOSE: Patients who have cancer have leveraged the Internet to gain a better understanding of their disease and connect across geographic boundaries with others facing the same challenges. Online cancer communities have developed into resources that highlight new research and evolving care pathways. Combined with increasing health literacy and social media, they have enabled some patients to become experts in their cancer. This combination of empowerment and expertise describes the new “e-patients.” METHODS: We reviewed the literature to identify key areas where expert e-patients have directly participated in advancing cancer medicine, as well as opportunities available to those who wish to become more involved in research advocacy. RESULTS: E-patients are widely acknowledged as key stakeholders in oncology by clinicians, researchers, cancer centers, government agencies, and nonprofits. Their input is vital for informing cancer care delivery, developing and launching research initiatives, creating care guidelines and pathways, and formulating policy. CONCLUSION: Expert e-patients play an expanded role in their own care and in larger conversations regarding practice, research, and policy. Clinicians can engage e-patients as partners in cancer care as we work together towards improving health care access and outcomes for people with cancer.

1 January 2015 in Breast Cancer: Basic and Clinical Research
Verified
Journal Article
Open access
JAJorge Luis Arroyo Acevedo
Jorge Luis Arroyo Acevedo
RCR.J. Chávez-Asmat
R.J. Chávez-Asmat
AAA. Anampa-Guzmán
A. Anampa-Guzmán
RDR. Donaires
R. Donaires
JRJosέ Ráez-Gonzáles
Josέ Ráez-Gonzáles
The possible protective effect of Piper aduncum capsule on DMBA (dimethylbenz[α]anthracene)-induced breast cancer in rats was assessed by monitoring the tumor and lung metastases incidence and recording hematological and biochemical parameters and frequency of micronuclei. Mammary carcinogenesis was induced in 36 female Holtzman rats by providing a single subcutaneous injection of DMBA. Oral administration of P. aduncum capsule lowered adenocarcinoma and lymph node metastases incidence. Pulmonary metastasis was significantly lowered ( P < 0.05). Hematological indicators showed that the triglyceride level was significantly lowered ( P < 0.01) and high-density lipoprotein (HDL) level was significantly increased ( P < 0.01). Also, P. aduncum capsule significantly lowered the C reactive protein (CRP) level ( P < 0.01) and malondialdehyde level ( P < 0.05). There was a significant decrease in the frequency of DMBA-induced micronucleated polychromatic erythrocyte ( P < 0.01). Considering the antitumorigenic, hypolipidemic, anti-inflammatory, antioxidant, and antigenotoxic properties of P. aduncum capsule, we conclude that it has a protective effect on DMBA-induced breast cancer in rats.

28 August 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
Narendranath EpperlaNarendranath Epperla
Narendranath Epperla
QZQiuhong Zhao
Qiuhong Zhao
RKReem Karmali
Reem Karmali
PTPallawi Torka
Pallawi Torka
LSLauren Shea
Lauren Shea
AOAdam J. Olszewski
Adam J. Olszewski
Given the paucity of data surrounding the prognostic relevance of monoclonal paraprotein (M-protein) in marginal zone lymphoma (MZL), we sought to evaluate the impact of detecting M-protein at diagnosis on outcomes in patients with MZL in a large retrospective cohort. The study included 547 patients receiving first-line therapy for MZL. M-protein was detectable at diagnosis in 173 (32%) patients. There was no significant difference in the time from diagnosis to initiation of any therapy (systemic and local) between the M-protein and no M-protein groups. Patients with M-protein at diagnosis had significantly inferior progression-free survival (PFS) compared with those without M-protein at diagnosis. After adjusting for factors associated with inferior PFS in univariate models, presence of M-protein remained significantly associated with inferior PFS (hazard ratio, 1.74; 95% confidence interval, 1.20-2.54; P = .004). We observed no significant difference in the PFS based on the type or quantity of M-protein at diagnosis. There were differential outcomes in PFS based on the first-line therapy in patients with M-protein at diagnosis, in that, those receiving immunochemotherapy had better outcomes compared with those receiving rituximab monotherapy. The cumulative incidence of relapse in stage 1 disease among the recipients of local therapy was higher in the presence of M-protein; however, this did not reach statistical significance. We found that M-protein at diagnosis was associated with a higher risk of histologic transformation. Because the PFS difference related to presence of M-protein was not observed in patients receiving bendamustine and rituximab, immunochemotherapy may be a preferred approach over rituximab monotherapy in this group and needs to be explored further.

1 December 2021 in JCO Global Oncology
Verified
Journal Article
Open access
AAAndrea Anampa-Guzmán
Andrea Anampa-Guzmán
FAFrancisco Acevedo
Francisco Acevedo
APAnn H. Partridge
Ann H. Partridge
CACatherine M. Alfano
Catherine M. Alfano
LNLarissa Nekhlyudov
Larissa Nekhlyudov
PURPOSE: The number of cancer survivors is increasing globally although the status of cancer survivorship care provision and research in developing countries is limited. This study aimed to review published literature and available guidelines and/or recommendations to inform cancer survivorship care in Latin America. METHODS: Embase, Web of Science, Scopus, PubMed, and SciELO were systematically searched for articles and guidelines and/or recommendations published through December 31, 2020. Our search terms included cancer, survivors, neoplasm, cancer, survivorship, survivor, follow-up studies, and the name of the countries. We categorized the articles by country, year, cancer type(s), language, and domain of cancer survivorship care. We also searched governmental health agencies websites in all Latin American countries. RESULTS: Our literature review found 664 articles for inclusion. The number of publications increased over time. Brazil had most of the survivorship research (n = 483, 72.7%). The most common topics included surveillance and management of psychosocial effects (n = 237, 35.7%) and physical effects (n = 230, 34.6%). Prevention and surveillance for recurrences and health promotion and disease prevention were each addressed by about 10% (n = 71) of the publications. Although close to half of the publications included more than one cancer, 28.9% (n = 192) focused solely on breast cancer. We found no guidelines and/or recommendations explicitly focusing on Latin America in the reviews of the literature or the national governmental institutions' websites. CONCLUSION: We found a growing body of cancer survivorship publications, mainly focusing on psychosocial and physical effects, although no cancer survivorship guidance and/or recommendations focused on Latin America were identified. Expanding research across Latin American countries and covering a broader spectrum of cancer survivorship care is needed. Development of guidelines may further promote provision of quality care for this growing population of cancer survivors.

18 October 2024 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
NGNatalie Grover
Natalie Grover
KAKaitlin Annunzio
Kaitlin Annunzio
MWMarcus Watkins
Marcus Watkins
PTPallawi Torka
Pallawi Torka
RKReem Karmali
Reem Karmali
Narendranath EpperlaNarendranath Epperla
Narendranath Epperla
Marginal zone lymphoma (MZL) can have varied presentations and pathologic features, including high Ki-67 expression ( > 20%) as well as increased numbers of large B cells (LC). However, there are limited data available demonstrating the prognostic significance of these variables in patients with MZL. In this multi-institutional retrospective cohort study of patients with MZL treated at 10 centers, we evaluated the association between the presence of Ki-67 expression and increased LCs on survival and risk of histologic transformation (HT). A total of 785 patients were included (60% with extranodal MZL, 20% with nodal MZL, and 20% with splenic MZL). Among the 440 patients with Ki-67 staining, 22% had high Ki-67 (Ki-67 >20%). The median progression-free survival (PFS) for patients with high Ki-67 was 5.4 years compared to 7.0 years for patients with low Ki-67 (HR = 1.45, 95%CI = 1.03–2.05). Ki-67 > 20% strongly correlated with high LDH level. The risk of HT was higher in patients with increased Ki-67 than those without (5-year risk, 9.8% vs 3.87%, p = 0.01). Twelve percent of patients had LC reported on biopsy with 6% having >10% LC. The presence of LC was associated with high Ki-67 (p < 0.001), but not associated with shorter PFS or overall survival (OS). The cumulative risk for HT was higher in patients with LC compared to those without LC (5-year risk, 9.4% vs 2.9%, p = 0.04). Receipt of anthracycline-based therapy did not impact PFS or OS in either group. Ki-67 staining >20% was a prognostic factor for worse survival and strongly correlated with elevated LDH. Novel therapies should be investigated for their potential ability to overcome the high-risk features in MZL. Our data reinforce the importance of obtaining biopsies at relapse or progression, particularly in patients with baseline high Ki-67 and increased LCs, given their increased risk for HT.

1 June 2017 in Prostate International
Verified
Journal Article
Open access
JAJorge Luis Arroyo Acevedo
Jorge Luis Arroyo Acevedo
Oscar Herrera-CalderonOscar Herrera-Calderon
Oscar Herrera-Calderon
RCRoberto Chávez-Asmat
Roberto Chávez-Asmat
AAAndrea Anampa-Guzmán
Andrea Anampa-Guzmán
VCVíctor Chumpitaz-Cerrate
Víctor Chumpitaz-Cerrate
EEEdwin Enciso-Roca
Edwin Enciso-Roca
The main objective was to evaluate the possible protective effect of Chuquiraga spinosa extract on N-methyl nitrosourea (NMU)-induced prostate cancer in rats and DU-145 cell line. Prostate carcinogenesis was induced in 30 male Holtzman rats by providing cyproterone acetate, testosterone, and NMU. The tumors were monitored and hematological and biochemical parameters and frequency of micronucleated polychromatic erythrocytes were recorded. The cell line was assessed by a cytotoxicity assay. Oral administration of C. spinosa extract significantly lowered superoxide dismutase malondialdehyde, NO, C-reactive protein, and prostate-specific antigen levels (all P < 0.01 compared with Inductor Group). There was a significant decrease in the frequency of micronucleated polychromatic erythrocytes (P < 0.05). C. spinosa presented a selectivity index of 17.24 in the cytotoxicity assay. Considering its anti-inflammatory, antioxidant, and antigenotoxic effects, and important variations on biochemical and hematological parameters, including prostate-specific antigen of C. spinosa extract, we conclude that it has a protective effect on NMU-induced prostate cancer in rats and cytotoxicity in the DU-145 cell line.